Image-based versus atlas-based patient-specific S-value assessment for Samarium-153 EDTMP cancer palliative care: A short study

Authors

  • Ahmad Bitarafan Rajabi Echocardiography Research Center, Cardiovascular Interventional Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran|Department of Nuclear Medicine, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  • Ali Parach Department of Medical Physics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  • Faraz Kalantari Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas, USA
  • Maryam Fallahpoor Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Mehrshad Abbasi Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
Abstract:

Introduction: Use of SPECT/CT data is the most accurate method for patient-specific internal dosimetry when isotopes emit single gamma rays. The manual or semi-automatic segmentation of organs is a major obstacle that slows down and limits the patient-specific dosimetry. Using digital phantoms that mimic patient’s anatomy can bypass the segmentation step and facilitate the dosimetry process. In this study, the results of a patient-specific dosimetry based on CT data and XCAT phantom, a flexible phantom with predefined organs, are compared. Methods: The dosimetry results (S-value and SAF) were calculated for a patient with breast cancer who received Samarium-153 ethylenediamine-N,N,N′,N′-tetrakis(methylenephosphonic acid (153Sm-EDTMP). Biodistribution of activity was obtained from the SPECT scan. The anatomical data and attenuation map were extracted from CT as well as the XCAT phantom with different BMIs. GATE Monte-Carlo simulator was used to calculate the dose to different organs based on the activity distribution and segmented anatomy. Results:The whole body dosimetry results are the same for both calculations based on the CT and XCAT with different BMIs; however for target organs, the differences between SAFs and S-values are high. In the spine, the clinically important target organ for Samarium therapy, the dosimetry results obtained from phantoms with unmatched BMIs between XCAT phantom and CT are substantially different. Conclusion: We showed that atlas-based dosimetry using XCAT phantom even with matched BMI may lead to considerable errors as compared to calculations based on patient’s own CT. For accurate dosimetry results, calculations should be done using CT data.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.

PURPOSE Many patients with metastatic bone disease have to use radiopharmaceuticals associated with chemotherapy to relieve bone pain. The aim of this study was to assess the influence of docetaxel on the biodistribution of samarium-153-EDTMP in bones and other organs of rats. METHODS Wistar male rats were randomly allocated into 2 groups of 6 rats each. The DS (docetaxel/samarium) group rece...

full text

Stakeholders’ Perceptions of Home-based Palliative Care for Cancer Patients During the COVID-19 Pandemic: A Qualitative Study

Background: During the COVID-19 pandemic, care for cancer patients may be disrupted for several reasons, leading to disease progression. Home-Based palliative care, if properly managed, can provide easy and safe access to care services for these patients. This study aimed to explore stakeholders’ perceptions of home-based palliative care for cancer patients during the pandemic. Methods: This q...

full text

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic castration-resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine tetramethylene phosphonate (Sm-153-EDTMP; Quadramet®), a radiopharmaceutical, binds osteoblastic bone lesions and emits beta particles causing local tumor cell destruction. Preclinically, Sm-153-EDTMP alters tumor cell phenotype facilitatin...

full text

Treatment of bone pain secondary to metastases using samarium-153-EDTMP.

CONTEXT More than 50% of patients with prostate, breast or lung cancer will develop painful bone metastases. The purpose of treating bone metastases is to relieve pain, reduce the use of steroids and to maintain motion. OBJECTIVE To evaluate the use of samarium-153-EDTMP (153Sm-EDTMP) for the treatment of bone pain secondary to metastases that is refractory to clinical management. TYPE OF S...

full text

Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP.

Forty dogs with spontaneous skeletal neoplasia were treated with 153Sm-EDTMP (ethylenediaminetetramethylene phosphonic acid). Both primary and metastatic lesions were treated. Two treatment regimes, a single (37 MBq (1.0 mCi)/kg dose or two 37 MBq (1.0 mCi)/kg doses separated by 1 wk) were tested. Response to treatment was varied. Large lesions with minimal tumor bone formation responded poorly...

full text

Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.

PURPOSE The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months af...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 26  issue 2

pages  76- 81

publication date 2018-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023